Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If the "go short" movement had any substance, it could take this back below .01 UNTIL the 13th, but as you can see, it struggles to keep it below .015. Load and hold. Nickles, dimes, and quarters, then dollars. Pick your exit point.
No doubt, but that same piece of information is brought up repeatedly with not even an attempt to substantiate it . . . as we know, because it is insubstantial!
I want to the board to see that this poster has NO EVIDENCE to back up the threat of suspension. VITX has not posted non-public information, therefore NO ONE could have bought or sold on the basis of that non-public information. Therefore, nothing illegal has been done. Period.
The ride here is soon going to make the crows fly back to Isengard!
Buying or selling a security on the basis of material nonpublic material information is prohibited under Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5 and 10b5-1 thereunder. Violators may be subject to civil and criminal penalties.
Yes. I did add some more at 1.38 - lawdy, have mercy! This is gonna be SOOOO much fun when she starts to run! I've got the time to wait for the dime.
They promised to be current with the OTC and also be approved to sell products in the USA with the FDA by the end of February ?
What are the odds that the SEC has eyes on VITX because of the STOP sign and being dark defunct and not be making material information publicly available
We all assumed they would report 2/28, but they never said they would. Now we wait for the unknown, but anticipated exhilirating filing.
I did what many of you did: added more today at 1.71.
Vitana-X Europe's revenue will be included when GHHC next reports its quarterly results, which is due by February 28, 2021.
What material information has VITX failed to make publicly available?
I don't think this company does PM press releases, so the "shorts" will have just enough time to get into trouble before the fins/pr.
Vitana-X Europe's revenue will be included when GHHC next reports its quarterly results, which is due by February 28, 2021.
They seemed pretty confident in Sept 2020 that they had everything in place to launch Q1 in the U.S.:
MIAMI, FL / ACCESSWIRE / September 29, 2020 / GH Capital, Inc. (OTC PINK:GHHC), through its Vitana-X subsidiary, a provider of comprehensive programs for greater well-being, fitness and health with a wellness network marketing program, is pleased to announce that the prelaunch phase for the U.S. and Canadian markets will be initiated in a few weeks. Vitana-X has already taken the appropriate steps in the areas of ??product approvals, logistics and administration.
The prelaunch phase will offer the possibility of pre-registration for business and cooperation partners. The official start is planned after the prelaunch phase and will take place in the first quarter of 2021.
I agree. There are many (too many) people who are easily parted from true wealth for the sake of 30 pieces of silver.
If you are thinking of a chess analogy, every piece is a "pawn" = controlled by the player, even the King and Queen. No other piece on the board gets to 'play' another piece. The question then is: "who is the 'player'"?
I agree. I've seen the light, been baptized, and am looking for streets of gold!
The company could not have been clearer:
Vitana-X Europe's revenue will be included when GHHC next reports its quarterly results, which is due by February 28, 2021.
In regards to the Company's OTC Markets listing, the company had to re-apply to register in order to be able to publish its quarterly and annual reports as an Alternative OTC reporting company. The application has been submitted and will be processed by OTC Markets. As soon it has been completed the annual report will be immediately published.
Little doubt now (if there ever was any) about the future of the company - just what the MMs are doing alone demonstrates the reality of increased revenues and massive growth. You gotta let'em play the games they love so well. As many others have said: patience is your best friend here. Don't get caught up in the day-to-day movements, which reflect realities we often may not understand. Know, and grow.
What gives in the land of the ARCS? Movement? Upward? Is that allowed here? Maybe the funeral was premature? Shall we find grave diggers to unearth the body? What say you??
So, some poor trader(s) "sold the news" - lol - some just never learn.
If it's not clear by now what is going to happen with real volume here when the catalysts start dropping, well . . . I'm not sure what else will convince you. Buy and hold, and reap the gold.
ARC$ popped to .08 on a "tweet". This has 1) news, 2) legitimacy, 3) revenue, 4) verified profile, 5) massive sales force, 6) top notch website, 7) and genetics in a genetically-driven world. People will pay dearly for the promise of feeling better. Did I miss something?
So, yeah, holders . . . don't sell cheap!
Bought some more this morning using TDA, so the 1/31 thing was clearly inaccurate or misleading or both.
One of two options:
1. Someone who had a few shares wanted to play somewhere else, or
2. Someone who sells shares to retail needed to buy more for what's about to happen . . .
Now, we start the run.
Could not agree more! Thanks for your persistence here as well!
Sandera,
Thanks for all your work on this one.
If anyone needs encouragement, I'm holding 13M shares from .0033; and I'll be glad to share when I'm selling, which is not on the horizon as yet. We literally are above .01 on NO NEWS . . . think about what is coming in terms of expansion and filings, etc.
100 Lin Reg channel on 30m shows upper band at .0105. Dip and rip? This will definitely not be a "sell the news" stock!
189M shares unrestricted in penny land! With big promise on the horizon, in a world where metals and precious metals are used increasingly in technology . . . what's not to like here, and especially at this price!?
The Harris presidency already causing a stir in the "stock-that-almost-was"? I'm ready! Bring on some real news!
One of the nicest charts I've seen in a while . . . not the heavenly spike of some (like ARCS pre-dump), but a good solid move up.
A couple hundred million shares traded on the heels of a nice juicy PR, and we are well into penny land, my friends! I like that they are not in a rush to release fluff PRs, like we have all seen many companies do. Give us a PR when there is something worth PRing!
The roving bands of pump-n-dump artists will eventually find this extremely low float pink current (whatever it really is) and run it up very high very quickly. Set your sell orders accordingly.
From the FDA's 2017 Warning Letter:
Your SVF product does not meet all of the criteria in 21 CFR 1271.10(a), and therefore does not qualify for regulation solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Specifically, your SVF product does not meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue, such as adipose tissue, in 21 CFR 1271.3(f)(1). Your product does not meet this criterion because your processing alters the original relevant characteristics of the adipose tissue relating to the tissue’s utility for reconstruction, repair, or replacement.
In addition, your SVF product fails to meet the 21 CFR 1271.10(a) (2) criterion that the HCT/P be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” As noted above, the SVF product is intended for use in the treatment of a variety of diseases or conditions. Because the SVF product is not intended to perform the same basic function or functions of adipose tissue, such as cushioning the body, using the SVF product for treatment of these diseases or conditions is not homologous use as defined in 21 CFR 1271.3(c). As a result, your SVF product does not qualify for regulation solely under section 361 of the PHS Act and 21 CFR Part 1271
The FDA is making the case that the issue at stake here is: what are the functions of adipose stems cell in fat? In other words, while those ASCs are in the fat tissue, what are they actually doing there? This is related to the homologous use issue. If in the fat they serve a regenerative function for X or Y tissue, etc., then it would be homologous use to take them out of the fat and introduce them into another part of the body where they are already serving that regenerative function. USRM believes they are following homologous use, due to the very nature of adult stem cells, which the FDA’s attorney made it appear as though the FDA did not have a clear understanding of!
Since the stem cells in adipose (fat) tissue stay there and wait until summoned by the body to perform some repairing function, I don't see how the FDA can overcome homologous use on any form of stem cell argument, if it is simple isolation and injection.
It is clear from Chamberlain’s arguments that the FDA has a HUGE problem with importing assumed definitions into its official guidance and the CFR language. She made ts clear that 1) they are not arguing that the FDA cannot regulate SVF, only that for seven years that FDA had provided an exception that allowed USRM to provide certain therapies, so, in fact, there was no regulation due to that exception, and 2) that the problem the FDA has is that of changing definitions and interpretative inconsistency. And students/people don’t think grammar or syntax matters . . . lol!
FDA has some serious explaining to do!
FDA Code: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=1271.10
Chinese wind farm next to an Air Force Base? What better place to have it? In Texas, we seldom miss . . .
Some subs have been launching much lower than VITX (for various reasons), but it's getting clearer and clearer that our true launch (filings, current, America news, etc.) will come at a higher SP than much of sub-land. I think it's a law of physics that, all things being equal, if you launch higher, you go farther . . .! JS
Yep. Better to have an early surprise than to lament a late expected one . . .
Announcement of PINK current will bring volume, more clarity on the American operation will also, as will the Q in about six weeks. And that is not considering what other news may be in the works. It's a good time to be here.
We don't really know, but I doubt it.
Good to hear!